Centessa Pharmaceuticals plc (NASDAQ:CNTA) EVP Antoine Yver Sells 9,200 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTAGet Rating) EVP Antoine Yver sold 9,200 shares of the stock in a transaction that occurred on Friday, June 17th. The stock was sold at an average price of $4.68, for a total value of $43,056.00. Following the completion of the transaction, the executive vice president now owns 739,697 shares in the company, valued at approximately $3,461,781.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Antoine Yver also recently made the following trade(s):

  • On Tuesday, May 17th, Antoine Yver sold 20,222 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $5.42, for a total value of $109,603.24.

Centessa Pharmaceuticals stock traded down $0.06 during mid-day trading on Tuesday, reaching $4.87. 132,802 shares of the company’s stock were exchanged, compared to its average volume of 246,495. The business’s fifty day simple moving average is $6.10 and its 200 day simple moving average is $8.48. The firm has a market capitalization of $457.98 million and a PE ratio of -2.05. Centessa Pharmaceuticals plc has a one year low of $2.88 and a one year high of $26.25. The company has a quick ratio of 21.37, a current ratio of 21.37 and a debt-to-equity ratio of 0.16.

Centessa Pharmaceuticals (NASDAQ:CNTAGet Rating) last issued its quarterly earnings results on Monday, May 16th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.09. On average, sell-side analysts forecast that Centessa Pharmaceuticals plc will post -2.18 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. increased its position in Centessa Pharmaceuticals by 263.3% in the fourth quarter. Point72 Asset Management L.P. now owns 1,097,908 shares of the company’s stock worth $12,362,000 after buying an additional 795,708 shares during the last quarter. Virtus ETF Advisers LLC purchased a new stake in Centessa Pharmaceuticals in the fourth quarter worth $167,000. JPMorgan Chase & Co. increased its position in Centessa Pharmaceuticals by 146.7% in the fourth quarter. JPMorgan Chase & Co. now owns 4,509 shares of the company’s stock worth $51,000 after buying an additional 2,681 shares during the last quarter. Kynam Capital Management LP increased its position in Centessa Pharmaceuticals by 179.9% in the first quarter. Kynam Capital Management LP now owns 669,100 shares of the company’s stock worth $6,002,000 after buying an additional 430,059 shares during the last quarter. Finally, OUP Management Co. LLC increased its position in Centessa Pharmaceuticals by 25.4% in the first quarter. OUP Management Co. LLC now owns 2,937,615 shares of the company’s stock worth $26,350,000 after buying an additional 595,724 shares during the last quarter. Institutional investors and hedge funds own 95.72% of the company’s stock.

A number of research analysts have recently weighed in on CNTA shares. Morgan Stanley dropped their target price on Centessa Pharmaceuticals from $19.00 to $15.00 and set an “overweight” rating on the stock in a report on Tuesday, May 24th. Jefferies Financial Group lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a report on Friday, June 3rd. BMO Capital Markets started coverage on Centessa Pharmaceuticals in a report on Thursday, June 16th. They issued an “outperform” rating and a $19.00 target price on the stock. Finally, The Goldman Sachs Group dropped their target price on Centessa Pharmaceuticals from $12.00 to $8.00 and set a “neutral” rating on the stock in a report on Tuesday, May 24th.

About Centessa Pharmaceuticals (Get Rating)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.

Featured Articles

Insider Buying and Selling by Quarter for Centessa Pharmaceuticals (NASDAQ:CNTA)

Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.